Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
ProKidney Corp.(PROK)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PROK
09/28/2026: PROK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
ProKidney Corp. is a clinical-stage biotechnology company focused on developing REACT, a proprietary autologous cell therapy intended to treat chronic kidney disease. Its main strength lies in its innovative, patient-specific approach which seeks to address a significant, unmet medical need in renal health. The company's primary growth opportunity is the potential to delay or prevent dialysis for patients, creating a massive addressable market. However, investors must consider high risks associated with the clinical-stage business model, including trial failure, execution hurdles, and valuation uncertainty. This stock best suits investors with a high risk tolerance and a long-term horizon who are monitoring progress through pivotal clinical trials.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The high-risk, high-reward nature of clinical-stage biotech offers speculative growth potential. |
| Momentum investor | Mixed fit | Momentum is conditional on positive clinical data readouts and upward price trends. |
| Value investor | Weak fit | Valuation is difficult to justify through traditional metrics as the company is pre-revenue. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on cash-intensive R&D. |
| Low-risk investor | Weak fit | The company's clinical stage and high volatility make it unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical trial news and sector-wide sentiment swings. |
| Valuation risk | High | Speculative valuation is prone to major corrections if clinical milestones are missed. |
| Competition risk (Pharma/CKD drugs) | Medium / high | Established players have massive resources to combat potential new entrants. |
| Business quality | Medium | The company relies on a single platform technology, creating high concentration risk. |
| Dividend income | Low / none | No cash flow is generated for distribution. |
| Execution risk | High | Successfully moving through regulatory and manufacturing hurdles is non-guaranteed. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -87.97% | Avg. Invested days 8 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 638.69M USD | Price to earnings Ratio - | 1Y Target Price 6.25 |
Price to earnings Ratio - | 1Y Target Price 6.25 | ||
Volume (30-day avg) 1.5M shares | Beta 1.75 | 52 Weeks Range 1.30 - 3.48 | Updated Date 09/27/2026 |
52 Weeks Range 1.30 - 3.48 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.55 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell Therapy R&D | Clinical trial development and intellectual property surrounding REACT. | The company currently makes no money; it burns cash to prove its technology works in clinical trials. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 204.30M | Price to Sales(TTM) 780.8 |
Enterprise Value 204.30M | Price to Sales(TTM) 780.8 | ||
Enterprise Value to Revenue 249.75 | Enterprise Value to EBITDA 2.13 | Shares Outstanding 208.93M | Shares Floating 184.65M |
Shares Outstanding 208.93M | Shares Floating 184.65M | ||
Percent Insiders 46.45 | Percent Institutions 26.37 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About ProKidney Corp.
Exchange NASDAQ | Headquarters Winston-Salem, NC, United States | ||
IPO Launch date 2022-07-12 | CEO & Director Dr. Bruce Culleton M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 231 | Website https://prokidney.com |
Full time employees 231 | Website https://prokidney.com | ||
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.